<DOC>
	<DOCNO>NCT02833857</DOCNO>
	<brief_summary>This multicenter , open-label study evaluate safety pharmacokinetics pediatric subject secondary hyperparathyroidism receive single dose AMG 416 end hemodialysis .</brief_summary>
	<brief_title>A Single-dose Study Paediatric Subjects Aged 2 Less Than 18 Years With ( sHPT ) Receiving Haemodialysis</brief_title>
	<detailed_description>A Single-dose Study Evaluate Safety Pharmacokinetics Paediatric Subjects Aged 2 less 18 Years ( sHPT ) Receiving Maintenance Haemodialysis</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Subject 's parent provide informed consent subject provide assent Children Age 2 less 18 year Diagnosed chronic kidney disease Diagnosed secondary hyperparathyroidism receive hemodialysis , Weighing least 7 kg Laboratory result within specified range . Currently receive treatment another investigation device drug study Subject receive cinacalcet therapy within 30 day History prolongation QT interval Subject take medication QT prolongation mediation list ECG measurement within specified range .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Secondary Hyperparathyroidism , chronic kidney disease , hemodialysis</keyword>
</DOC>